EGFR mutation + CDKN2A mutation	Non Small Cell Lung Cancer	EGFR mutation + CDKN2A mutation	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR mutation + CDKN2A mutation	Non Small Cell Lung Cancer	EGFR mutation + CDKN2A mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3

EGFR mutation + CDKN2A mutation

Associations